Show simple item record

dc.contributor.authorSørbye, Sveinung Wergeland
dc.contributor.authorFismen, Silje
dc.contributor.authorGutteberg, Tore Jarl
dc.contributor.authorMortensen, Elin Synnøve
dc.contributor.authorSkjeldestad, Finn Egil
dc.date.accessioned2013-04-26T09:20:03Z
dc.date.available2013-04-26T09:20:03Z
dc.date.issued2013
dc.description.abstractBackground: In delayed HPV triage women with atypical squamous cells of uncertain significance (ASC-US) cytology are retested after 6-12 months in order to decide whether they should be referred for colposcopy, further follow-up cytology or routine screening in three years. Triage using a specific HPV E6/E7 mRNA test may reduce referrals for colposcopy of women with ASC-US cytology compared to HPV DNA testing. We explored whether HPV mRNA triaging could reduce the time from ASC-US index cytology to biopsy compared with repeat cytology, and whether the positive predictive value (PPV) of the HPV mRNA test for high grade cervical intraepithelial neoplasia (CIN2+) was comparable with the PPV of repeat cytology. Material and methods: We used repeat cytology and the HPV mRNA test PreTect HPV-Proofer, which detects E6/E7 mRNA from HPV subtypes 16, 18, 31, 33 and 45, in the triage of women with ASC-US. We included all women from the two northernmost counties of Norway with a first ASC-US cytology during the period 2004-2008. Two triage methods were evaluated 1) only repeat cytology (n=964) and 2) both HPV mRNA testing and cytology (n=542). Histologically confirmed CIN2+ was the study endpoint. Results: Among 1506 women with an ASC-US index cytology, 59 women (3.9%) had biopsy taken, of whom 49 women had CIN2+ (PPV 83.1%). The mean time from index ASC-US cytology until the case was resolved (biopsy or return to screening) was 10.6 months in the repeat cytology group and 7.3 months in the HPV group (P<0.001). Of the 964 women in the group with repeat cytology only, 35 women (3.6%) had biopsy and 30 had CIN2+ (PPV 85.7%). Of the 542 women in the group with both HPV test and cytology, 24 women (4.4%) had biopsy and 19 had CIN2+ (PPV 79.2%). Conclusion: In triage of women with ASC-US, the HPV mRNA test significantly reduced the time from the first abnormal cytology until biopsy and had predictive values comparable with those of repeat cytology.en
dc.identifier.citationCurrent Pharmaceutical Design (2013), vol.19 (8):1401-1405en
dc.identifier.cristinIDFRIDAID 949637
dc.identifier.doihttp://dx.doi.org/10.2174/138161213804805487
dc.identifier.issn1381-6128
dc.identifier.urihttps://hdl.handle.net/10037/5132
dc.identifier.urnURN:NBN:no-uit_munin_4844
dc.language.isoengen
dc.publisherBentham Science Publishersen
dc.rights.accessRightsopenAccess
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Gynecology and obstetrics: 756en
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Gynekologi og obstetrikk: 756en
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en
dc.titleHPV mRNA testing in triage of women with ASC-US cytology may reduce the time for CIN2+ diagnosis compared with repeat cytology.en
dc.typeJournal articleen
dc.typeTidsskriftartikkelen
dc.typePeer revieweden


File(s) in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record